Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine

Movement Disorders

Volumn 24, Issue 1, 2009, Pages 126-129

  Brusa, Livia ^a   Orlacchio, Antonio ^b,c   Moschella, Vincenzo ^c   Iani, Cesare ^a   Bernardi, Giorgio ^b,c   Mercuri, Nicola Biagio ^b,c  

^a S EUGENIO HOSPITAL   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Aripiprazole; Huntington's disease; Neuroleptics; Tetrabenazine

Indexed keywords

ARIPIPRAZOLE; TETRABENAZINE;

ADULT; AGED; ARTICLE; CHOREA; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DISABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MOTOR PERFORMANCE; PRIORITY JOURNAL; RATING SCALE; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOM;

ADULT; AGED; CROSS-OVER STUDIES; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; HUNTINGTON DISEASE; HYPERKINESIS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PIPERAZINES; QUINOLONES; RECEPTORS, DOPAMINE D2; TETRABENAZINE; TRINUCLEOTIDE REPEATS;

EID: 61449249292     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22376     Document Type: Article

References (15)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease. Cell 1993;72:971-983.
2. Van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997;63:35-39.
3. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22:193-197.
4. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-1411.
5. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63:763-771.
6. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3.
7. Canas F. Management of agitation in the acute psychotic patient-efficacy without excessive sedation. Eur Neuropsychopharmacol 2007;17:S108-S114.
8. 2 receptor partial agonist. J Med Invest 2005;52:284-290.
9. Gershon AA, Vishne T, Grunhaus L. Dopamine D2-like receptors and the antidepressant response. Biol Psychiatry 2007;61: 145-153.
10. Singh AS. Does aripiprazole have a role in treating cognitive impairment in Parkinson's disease? J Neuropsychiatry Clin Neurosci 2007;19:205-206.
11. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372.
12. Tedroff J, Ekesbo A, Sonesson C, Waters N, Carlsson A. Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease. Neurology 1999;53:1605-1606.
13. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry 2003;48:771-772.
14. Davies L, Stern JS, Agrawal N, Robertson MM. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006;21:447-453.
15. Ben Djebara M, Worbe Y, Schüpbach M, Hartmann A. Aripiprazole: a treatment for severe coprolalia in "refractory" Gilles de la Tourette syndrome. Mov Disord 2008;23:438-440.